In one paragraphArticle in Biotech (Basel (Switzerland)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Paulo Henrique Guilherme BorgesPost-Graduate Program in Microbiology, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.
Barbara GregioPost-Graduate Program in Microbiology, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.
Helena Tiemi SuzukawaLaboratory of Molecular Biology of Microorganisms, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.ORCID 0000-0002-2694-6553 Gislaine Silva-RodriguesPost-Graduate Program in Microbiology, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.
Emanuella de Castro AndreassaCarlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ-PR), Curitiba 81350-010, Brazil.ORCID 0000-0002-3297-5529 Isabela Madeira de CastroPost-Graduate Program in Microbiology, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.
Guilherme Bartolomeu-GonçalvesPost-Graduate Program in Clinical and Laboratory Physiopathology, State University of Londrina, Londrina 86.055-900, Brazil.ORCID 0000-0002-3497-5362 Emerson José VenancioDepartment of Immunology, Parasitology and General Pathology, State University of Londrina, Londrina 86.055-900, Brazil.ORCID 0000-0002-3735-9207 Phileno Pinge-FilhoDepartment of Immunology, Parasitology and General Pathology, State University of Londrina, Londrina 86.055-900, Brazil.ORCID 0000-0002-1500-3998 Viviane Monteiro GóesInstitute of Molecular Biology of Paraná, Curitiba 81350-010, Brazil.
Celso Vataru NakamuraLaboratory of Technological Innovation in the Development of Pharmaceuticals and Cosmetics, State University of Maringá, Maringá 87020-900, Brazil.ORCID 0000-0002-9911-7369 Eliandro Reis TavaresLaboratory of Molecular Biology of Microorganisms, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.
Tatiana de Arruda Campos Brasil de SouzaCarlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ-PR), Curitiba 81350-010, Brazil.
Sueli Fumie Yamada-OgattaLaboratory of Molecular Biology of Microorganisms, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.ORCID 0000-0003-1183-146X Lucy Megumi YamauchiLaboratory of Molecular Biology of Microorganisms, Department of Microbiology, State University of Londrina, Londrina 86.055-900, Brazil.ORCID 0000-0003-2241-8814 Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior 01Fundação Araucária 2022011000171Fundação Araucária 219/2023National Council for Scientific and Technological Development 402387/2020-1
6 · The paper itselfAbstract
This study reports the construction, expression, and purification of synthetic SARS-CoV-2 spike (S) and nucleoprotein (N) containing immunodominant epitopes. The pET28aS_epit construct included epitopes 287-317, 402, 507, 524-598, and 601-640, while the pET28aN_epit construct included residues 42-62, 153-172, and 355-401. Commercial sequences of both proteins were used as controls. The four constructs were expressed using the
Indexed as
immunoinformaticspurification of recombinant proteinsSARS-CoV-2synthetic biology
Identifiers
PMID40558387
PMCPMC12191430
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390